Zymogenetics, Inc.

Bristol-myers Squibb Compnay

Thomas R Bukowski

Paul O Sheppard

Kevin M Klucher

Dennis L Dong

Lowell J Brady

Chung Chan

Hong Yan Liu

Darrell C Conklin

Theresa A Deisher

Susan D Holderman

Fenella C Raymond

Birgit Hansen

Hong Liu

Chung-Leung Chan

Paul D Bishop

Christopher K Raymond

Susan D Julien

Brigit Hansen

Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.

Mutants of IL-29

Method of using IL-29 cystehne mutant to treat hepatitis C and hepatitis B

Method of using IL-29 cysteine mutant to treat hepatitis C and hepatitis B

Polynucleotide encoding an IL-28A polypeptide

Polynucleotide encoding an IL-28A polypepide

Polynucleotide encoding an IL-28B polypeptide

Polynucleotide encoding an il-29 polypeptide

Polynucleotide encoding an IL-29 polypeptide

Growing community of inventors

Seattle, WA, United States of America

Thomas R Bukowski